From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Synairgen – Where are we now with the one Covid play I liked?

By Peter Brailey | Wednesday 11 November 2020


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Is it just me or is the rest of the world moving incredibly quickly while I put up with the second lockdown. Or as I refer to it “mockdown” – with my children still going to school and interacting with half the local villages and towns. Not only does The Donald win / lose / win??? again (if one accepts some the US news feeds), we now have a vaccine for Covid. Apparently. I’m sure the infrastructure to distribute and store a product that requires -80 degrees is well within the capabilities of our fearsome leaders to sort – after all distributing and storing PPE (like masks) is far more difficult and they did that without any problem I recall. So where does that leave me in my thinking for Synairgen (SNG)?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 11:49:25